IR@PKUHSC  > 北京大学第一临床医学院  > 大内科
学科主题临床医学
FCGR3A 158V/F Polymorphism and Response to Frontline R-CHOP Therapy in Diffuse Large B-Cell Lymphoma
Liu, Fen1,2; Ding, Huirong3; Jin, Xuan4; Ding, Ning5; Deng, Lijuan5; He, Yan1,2; Zhu, Jun5; Song, Yuqin5
刊名DNA AND CELL BIOLOGY
2014-09-01
DOI10.1089/dna.2013.2333
33期:9页:616-623
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Biochemistry & Molecular Biology ; Cell Biology ; Genetics & Heredity
研究领域[WOS]Biochemistry & Molecular Biology ; Cell Biology ; Genetics & Heredity
关键词[WOS]FC-GAMMA-RIIIA ; ELDERLY-PATIENTS ; RITUXIMAB ; SURVIVAL ; METAANALYSIS ; EFFICACY
英文摘要

The influence of Fc gamma receptor IIIA (FCGR3A) 158V/F polymorphisms on the response to rituximab (R) plus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone; R-CHOP) therapy in diffuse large B-cell lymphoma (DLBCL) is uncertain. Thus, a retrospective study and a meta-analysis were performed to examine the possible correlation between FCGR3A 158V/F polymorphism and the response rate of R-CHOP regimen in patients with newly diagnosed DLBCL. The genotypes of FCGR3A 158V/F in 164 newly diagnosed DLBCL patients treated with R-CHOP were determined in this retrospective study. Additionally, a meta-analysis of current and previously published studies was conducted. Overall response rate (complete and partial response, ORR) and complete response rate (CR) were evaluated. The results of our retrospective study showed lack of correlation between FCGR3A 158V/F polymorphism and ORR (p = 0.78) or CR (p = 0.76) with R-CHOP therapy. A meta-analysis of 731 cases also showed lack of significant association of ORR and CR in all genetic models with FCGR3A 158V/F polymorphism. In survival analysis, the homozygous F genotype correlated with a shorter progression-free survival than that of non-F/F genotype (p = 0.05), this was significant for the non-GC subset of DLBCL (p = 0.04), but no association was found between overall survival and FCGR3A 158V/F polymorphism. Further analysis with nonsuperiority test (p < 0.0001) suggested that FCGR3A 158V/F polymorphism was not associated with better ORR or CR in newly diagnosed DLBCL patient treated with R-CHOP. No clear relationship was found between FCGR3A 158V/F polymorphism and response to frontline R-CHOP therapy in patients with DLBCL.

语种英语
WOS记录号WOS:000341507400006
项目编号30973484
资助机构National Science Foundation Committee (NSFC) of China
引用统计
被引频次:7[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/51330
专题北京大学第一临床医学院_大内科
北京大学第一临床医学院_肿瘤化疗科
北京大学临床肿瘤学院_淋巴肿瘤内科
北京大学临床肿瘤学院_中心实验室
作者单位1.Beijing Municipal Key Lab Clin Epidemiol, Beijing, Peoples R China
2.Capital Med Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Beijing, Peoples R China
3.Peking Univ, Canc Hosp & Inst, Dept Lymphoma,Cent Lab, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
4.Peking Univ, Hosp 1, Dept Internal Med, Beijing 100871, Peoples R China
5.Peking Univ, Canc Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
推荐引用方式
GB/T 7714
Liu, Fen,Ding, Huirong,Jin, Xuan,et al. FCGR3A 158V/F Polymorphism and Response to Frontline R-CHOP Therapy in Diffuse Large B-Cell Lymphoma[J]. DNA AND CELL BIOLOGY,2014,33(9):616-623.
APA Liu, Fen.,Ding, Huirong.,Jin, Xuan.,Ding, Ning.,Deng, Lijuan.,...&Song, Yuqin.(2014).FCGR3A 158V/F Polymorphism and Response to Frontline R-CHOP Therapy in Diffuse Large B-Cell Lymphoma.DNA AND CELL BIOLOGY,33(9),616-623.
MLA Liu, Fen,et al."FCGR3A 158V/F Polymorphism and Response to Frontline R-CHOP Therapy in Diffuse Large B-Cell Lymphoma".DNA AND CELL BIOLOGY 33.9(2014):616-623.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Liu, Fen]的文章
[Ding, Huirong]的文章
[Jin, Xuan]的文章
百度学术
百度学术中相似的文章
[Liu, Fen]的文章
[Ding, Huirong]的文章
[Jin, Xuan]的文章
必应学术
必应学术中相似的文章
[Liu, Fen]的文章
[Ding, Huirong]的文章
[Jin, Xuan]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。